Navigation Links
Cynvenio and Saint Luke’s Cancer Institute Launch Pilot Study to Evaluate the Potential for Early Detection of Recurrent Breast Cancer Following Therapy
Date:8/17/2017

Cynvenio Biosystems, Inc., a leader in liquid biopsy technology for cancer research and personalized medicine, today announced the launch of a new breast cancer monitoring study in partnership with Saint Luke’s Cancer Institute in Kansas City, Missouri. The study’s goal is to evaluate the potential for early detection of recurrent breast cancer using LiquidBiopsy and natural killer (NK) cell testing in patients at high-risk of relapse after neoadjuvant chemotherapy.

The first phase of the new study will test patients who are scheduled to receive neoadjuvant chemotherapy before surgery, while the second phase will test patients after their surgery. Cynvenio’s proprietary ClearID Breast Cancer test sequences 27 genes commonly mutated in breast cancer and analyzes cell-free DNA (cfDNA) and circulating tumor cells (CTCs) pre- and post- treatment while assessing the correlation of NK cell activity to a patient’s response to chemotherapy. The study is expected to help determine whether surveillance of CTC and NK cells can predict subsequent clinical relapse following neoadjuvant therapy.

“We know that some patients with early stage breast cancer will have systemic recurrence. At present we lack a reliable method of early detection of relapse. The hope is that early detection will lead to more effective treatment. This technology not only allows surveillance of CTC and cfDNA that may predict eventual relapse, it also monitors the innate immune system of the patient,” said Dr. Timothy Pluard, Medical Director of the Saint Luke’s Cancer Institute. “Saint Luke’s Cancer Institute is excited to partner with Cynvenio for this pilot study to determine the potential for early detection utilizing LiquidBiopsy technology and the potential impact this could have for patients.”

“We are enthused and honored to collaborate with Dr. Pluard and his outstanding team to highlight the clinical utility of our multi-template approach to serial monitoring of breast cancer, along with our NK cell activity test,” said Paul Y. Song, MD, Cynvenio’s Chief Medical Officer. “Based on preliminary data from our Triple Negative Breast Cancer trial and from our Danish clinical partners with our NK Score test, we believe that the combination of these two tests may provide a better insight into the overall cancer biology of each patient.”

About Saint Luke’s Health System
Saint Luke’s Cancer Institute is a part of Saint Luke’s Health System which consists of 10 area hospitals and campuses and several primary and specialty care practices, and provides a range of inpatient, outpatient, and home care services. Founded as a faith-based, not-for-profit organization, our mission includes a commitment to the highest levels of excellence in health care and the advancement of medical research and education. The health system is an aligned organization in which the physicians and hospitals assume responsibility for enhancing the physical, mental, and spiritual health of people in the metropolitan Kansas City area and the surrounding region.

About Cynvenio Biosystems, Inc.
Cynvenio’s liquid biopsy testing technology is leading the way to more affordable and clinically actionable precision medicine strategies for cancer patients.  Among the company’s breakthroughs is its line of ClearID® tests for greatly improved cancer detection and monitoring via a patient-friendly blood draw, and a suite of proprietary, distributable LiquidBiopsy® platforms and consumables for deployment in hospitals and third party diagnostic labs. Cynvenio is based in Westlake Village, California. For more information, please visit http://www.cynvenio.comhttp://www.clearidmonitoring.com, and http://www.liquidbiopsy.com.

LiquidBiopsy® and ClearID® are registered trademarks of Cynvenio Biosystems, Inc.

Read the full story at http://www.prweb.com/releases/2017/08/prweb14601181.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Cynvenio Biosystems to Present Clinical Data on Mutational Analysis of LiquidBiopsy® Tumor Samples at the 2013 ASCO Annual Meeting
2. Cynvenio Biosystems Receives CLIA Certification for its Genomic Sequencing Laboratory
3. Cynvenio and CollabRx Announce Partnership for Cancer Molecular Diagnostics
4. Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test
5. Cynvenio Biosystems Announces Expansion of Payer Network with Addition of Blue Cross Blue Shield of Illinois
6. Cynvenio Releases Two New High Recovery LiquidBiopsy® CTC Capture Kits at 2017 AACR Annual Meeting in Washington, DC.
7. Cynvenio and TME Research Announce Neoadjuvant Breast Cancer Monitoring Study (NEAT)
8. Cynvenio Releases ClearID® Lung Cancer: a Highly-Targeted Genomic Blood Test for Lung and Thoracic Cancer Patients
9. Cynvenio Research Highlights Need for Longitudinal Monitoring of Triple Negative Breast Cancer Patients
10. Cynvenio’s LiquidBiopsy® Platform-Derived Research Data to be Presented at the 2017 ASCO Annual Meeting, June 2-June 6, 2017 in Chicago, Illinois
11. Cynvenio Announces ClearID® Commercial Distribution Agreements for Israel, Greece, Argentina and South Korea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... a United States multicenter, prospective clinical study that demonstrates the accuracy of ... capable of identifying clinically significant acute bacterial and viral respiratory tract infections ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... President Andi Purple announced Dr. Suneel I. Sheikh, the co-founder, CEO and ... Labs ), Inc. has been selected for membership in ARCS Alumni Hall ...
(Date:10/11/2017)... ... 2017 , ... Proscia Inc ., a data solutions ... “Pathology is going digital. Is your lab ready?” with Dr. Nicolas Cacciabeve, Managing ... how Proscia improves lab economics and realizes an increase in diagnostic confidence.* ...
(Date:10/11/2017)... TX (PRWEB) , ... October 11, 2017 , ... ... August compared the implantation and pregnancy rates in frozen and fresh in ... contribution of progesterone and maternal age to IVF success. , After comparing the ...
Breaking Biology Technology:
(Date:8/23/2017)... Aug. 23, 2017  The general public,s help is being enlisted in ... that live in and on the human body –and are believed to ... The Microbiome Immunity Project ... microbiome, starting with the gut. The project's goal is to help advance ... IBM ...
(Date:6/30/2017)... Va. , June 30, 2017 ... leading developer and supplier of face and eye ... ATA Featured Product provider program. ... an innovative way to monitor a driver,s attentiveness ... greatly from being able to detect fatigue and ...
(Date:5/23/2017)... first robotic gym for the rehabilitation and functional motor sense evaluation of ... Italy . The first 30 robots will be available from June ... . The technology was developed and patented at the IIT laboratories and ... thanks to a 10 million euro investment from entrepreneur Sergio Dompè. ... ...
Breaking Biology News(10 mins):